Trial Profile
A Phase II, 4-Week Randomised, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs ISC 17536 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 13 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine.
- 01 Jun 2022 Primary endpoint (the change from baseline to end of treatment (i.e., baseline to end of week 4) in the mean 24-hour average pain intensity (API) score based on an 11 point pain intensity numeric rating scale (NRS)) has not been met, according to Results published in the Pain.
- 01 Jun 2022 Results published in the Pain